C WorldWide Group Holding A S Purchases New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

C WorldWide Group Holding A S acquired a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 95,000 shares of the company's stock, valued at approximately $3,587,000. C WorldWide Group Holding A S owned about 0.07% of Vaxcyte as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of PCVX. Capital Research Global Investors increased its position in Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares during the last quarter. Norges Bank purchased a new stake in Vaxcyte during the fourth quarter valued at $90,069,000. Vanguard Group Inc. increased its position in Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after acquiring an additional 521,204 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Vaxcyte by 57.3% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after acquiring an additional 518,255 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Vaxcyte in the fourth quarter worth about $39,846,000. Hedge funds and other institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of analyst reports. Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. The Goldman Sachs Group reduced their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Finally, Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded up $0.55 during mid-day trading on Monday, reaching $36.76. The company's stock had a trading volume of 252,951 shares, compared to its average volume of 1,492,784. The firm has a market capitalization of $4.74 billion, a PE ratio of -9.21 and a beta of 1.19. The stock has a fifty day moving average of $33.84 and a two-hundred day moving average of $53.44. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the previous year, the company earned ($0.85) earnings per share. Analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.